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Introduction
Historically, managing patients with acute renal failure 
suﬀ ered, in part, from a lack of consensus regarding 
deﬁ nition. Th is has been addressed, to a degree, with the 
introduction of diagnostic criteria based on changes in 
both serum creatinine and urine output. Th e RIFLE 
(Risk  - Injury  - Failure  - Loss  - End stage renal disease) 
criteria were developed in order to describe patients in 
terms of conventional markers of renal function, allowing 
cohort selection for studying intervention [1]. Hence, the 
term acute kidney injury (AKI) has gained popularity, 
although these criteria are not diagnostic and do not 
confer a cause for AKI but instead alert the clinician to 
the occurrence of biochemical and physiological changes 
in keeping with renal insuﬃ  ciency. Th e RIFLE criteria 
were subsequently modiﬁ ed by the AKI Network (AKIN) 
group [2]. Numerous publications have ‘validated’ the 
RIFLE and AKIN classiﬁ cations in terms of patient 
outcome prominently in the ICU arena. Interest into 
patients with AKI in the United Kingdom was galvanized 
following the publication of the National Conﬁ dential 
Enquiry into Patient Outcomes and Death (NCEPOD) 
report Adding Insult to Injury in 2009, which highlighted 
inadequacies in care for up to 50% of patients with AKI 
predominantly admitted to general wards [3].
In everyday practice, clinicians presented with a patient 
with a raised serum creatinine face several clinical 
challenges including: diﬀ erentiation between pre-renal 
azotaemia, AKI and stable chronic kidney disease (CKD); 
estimation as to the degree of renal dysfunction 
compared to baseline; estimation of the chances of renal 
recovery and need for renal replacement therapy (RRT); 
and decisions with regard to any speciﬁ c management
In 2005, the American Society of Nephrology Renal 
Research Report assigned the highest research priority to 
the standardization and/or discovery of new biomarkers 
of AKI driven by the awareness that even relatively 
‘trivial’ increases in serum creatinine were associated 
with considerable increases in the utilisation of health 
resources [4]. Since then, we have seen a proliferation of 
studies focussing on the detection and validation of new 
biomarkers in a variety of diﬀ erent patient populations 
and clinical settings.
Any potentially clinically useful candidate AKI bio-
marker(s) should ideally fulﬁ l several criteria, as outlined 
in Table  1. When one examines the performance of the 
existing AKI biomarkers against these criteria the results 
are variable, and their diagnostic and prognostic value in 
clinical practice outside a well deﬁ ned research setting is 
somewhat unreliable. Th e purpose of this review is to 
summarize recent ﬁ ndings concerning biomarkers for 
AKI in adult patient populations, including patients in 
the ICU, to highlight their strengths and weaknesses, and 
to determine their usefulness in clinical practice.
Diff erent biomarkers evaluated in clinical trials
Recently identiﬁ ed biomarkers of AKI are either low 
molecular weight proteins that are present in the 
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systemic circulation and undergo glomerular ﬁ ltration 
(that is, markers of glomerular function), enzymes that 
are released by tubular cells into the urine after tubular 
cell injury (that is, markers of tubular damage) or inﬂ am-
matory mediators released by renal cells or inﬁ ltrating 
inﬂ ammatory cells (that is, markers of degree of damage 
and indicators of site of injury) (Figure  1 and Table  2). 
Th e aetiology of AKI is far from uniform, however, and 
deﬁ ning new biomarkers for AKI is thus extremely 
challenging. Consequently, investigators have tended to 
study their chosen biomarker(s) in well deﬁ ned clinical 
settings where the timing of renal injury is known, that is, 
after cardiopulmonary bypass surgery, coronary angio-
graphy or following renal transplantation (Table 3). Further-
more, a signiﬁ cant number of studies were done in 
paediatric populations where comorbidities such as CKD, 
diabetes mellitus and chronic inﬂ ammatory diseases are 
less likely to present as confounding variables. As a result, 
not all studies are easily generalized to heterogenous 
populations, including critically ill patients in the ICU. 
Th e eﬀ ects of baseline renal function, comorbidities, age, 
and duration of renal injury have led to conﬂ icting results 
in various studies (Table 3).
Specifi c clinical scenarios
Diff erentiation between ‘pre-renal’ and ‘intrinsic’ acute 
kidney injury
Th e diﬀ erentiation between a transient serum creatinine 
rise caused by perturbations in renal perfusion and direct 
damage to the kidney leading to sustained AKI can be 
diﬃ  cult, especially in acute patients. Th e diagnosis of 
pre-renal AKI is usually retrospective after a transient 
rise in serum creatinine with recovery of function within 
24 to 72  hours. In a study involving 510 critically ill 
patients, De Geus and colleagues [5] conﬁ rmed that serial 
measurement of urinary neutrophil gelatinase-associated 
lipocalin (NGAL) could distinguish between these two 
conditions. Adding the results to a clinical prediction 
model, however, only led to marginal improvement of the 
area under the receiver operating characteristics curve 
(AUC) from 0.79 to 0.82. Nickolas and colleagues [6] 
evaluated ﬁ ve diﬀ erent urinary biomarkers (NGAL, 
kidney injury molecule (KIM)-1, liver-type fatty acid-
binding protein (L-FABP), IL-18, and cystatin C) in 1,635 
patients who presented to the emergency department 
and were subsequently hospitalized for more than 
24  hours. Th e entire cohort was divided into three 
subgroups: patients with sustained AKI (that is, AKI that 
persisted for more than 72 hours); patients with transient 
AKI (that is, AKI that resolved within 72  hours); and 
patients without AKI. All markers were raised in patients 
with sustained AKI but only urinary NGAL (uNGAL) 
and urinary cystatin C were able to distinguish patients 
with sustained AKI from those with transient or pre-
renal AKI. Hall and colleagues [7] measured uNGAL, 
Table 1. Desirable criteria for any potentially clinically useful candidate acute kidney injury biomarker(s)
To provide information above that of traditional clinical evaluation and investigation
To be non-invasive, utilising easily accessible samples
To provide results rapidly and both sensitive and specifi c to AKI
To have specifi c cutoff  values to distinguish between normal and abnormal renal function
To distinguish intrinsic AKI from pre-renal azotaemia
To provide insight into aetiology of AKI
To diff erentiate between AKI and chronic kidney disease
To be specifi c for renal injury in the presence of concomitant dysfunction of other organs
To be indicative of the severity of AKI
To ideally allow some estimate as to the timing of the onset of renal injury
To guide initiation of therapies and to monitor the response to interventions
To aid prognostication in terms of potential renal recovery, need for RRT and mortality
AKI, acute kidney injury; RRT, renal replacement therapy.
Figure 1. Origin of acute kidney injury biomarkers within 
a single nephron. GST, glutathione S-transferase; GT, glutamyl 
transpeptidase; KIM, kidney injury molecule; L-FABP, liver-type fatty 
acid-binding protein; NAG, N-acetyl-β-D-glucosaminidase; NGAL, 
neutrophil gelatinase-associated lipocalin; RBP, retinol binding 
protein.
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Table 3. Clinical studies of common acute kidney injury biomarkers in adult patients
AKI biomarker Results in clinical studies
Neutrophil 
gelatinase-associated 
lipocalin (NGAL)
Prediction of AKI:
    Post-cardiopulmonary bypass surgery [32,53-63]
    After contrast exposure [64,65]
    In sepsis [66,67]
    In trauma patients [68]
    In critically ill adult patients [13,36]
    In delayed graft function after renal transplantation [24,25,69]
Prediction of:
    Progression of AKI [7,20]
    Duration and severity of AKI and length of stay in ICU [54,55]
    Adverse outcomes in patients with AKI [70]
    Need for RRT [11,12,31,54,56,60-62]
    Mortality in patients on RRT [71]
    Need for RRT or death after cardiac surgery [63]
    Severity of AKI and need for RRT in patients in the emergency department [19,31]
    Recovery of AKI after pneumonia [23]
    GFR in patients with chronic kidney disease [72]
Diff erentiation between transient and sustained AKI in adults on admission to ICU [5,6], and between ‘pre-renal’ and intrinsic AKI [8,9]
Cystatin C Prediction of AKI:
    In critically ill adults [13,73]
    Post-cardiac surgery [56,74]
    In liver transplant recipients [75]
    Post-coronary angiography [65,76]
    In critically ill patients with baseline estimated GFR <60 ml/minute [13]
Prediction of:
    Severity and duration of AKI and length of ICU stay post-cardiac surgery [55]
    RRT in critically ill patients [16,21,27], post-cardiac surgery [54,56] and in patients with AKI seen by nephrology consult service 
[28,77,78]
Correlation with AKI post-cardiac surgery [74]
No improved prediction of AKI in adult renal transplant recipients [79] or ICU patients [80]
IL-18 Prediction of AKI:
    After renal transplantation [81,82]
    Post-cardiac surgery [63,82]
    In patients with acute lung injury [83]
    In critically ill patients [13]
Prediction of:
    14-day mortality in critically ill patients [17]
    Progression of AKI [7,20]
    Need for RRT or death after cardiac surgery [63]
    Mortality in patients with acute lung injury [83]
Kidney injury 
molecule-1 (KIM-1)
Prediction of AKI:
    Post-cardiac surgery [53,84,85]
    In critically ill patients [13,86]
    In patients with AKI seen by nephrology consult service [29]
    In critically ill patients with baseline estimated GFR <60 ml/minute [13]
Prediction of adverse outcome in hospitalized patients with AKI [7,29] 
Liver-type fatty acid 
binding protein 
(L-FABP)
Prediction of:
    AKI in critically ill patients [17]
    Poor outcome in patients with AKI [87]
    AKI post coronary angiography [88]
N-acetyl-β-D-
glucosaminidase 
(NAG)
Prediction of:
    AKI post cardiac surgery [56]
    Adverse events in patients with AKI [29]
Weak predictor of AKI in critically ill patients [17]
Urine α and 
п glutathione 
S-transferase (αGST 
and пGST)
Prediction of RRT in patients with non-oliguric acute tubular necrosis [78]
Inconsistent data regarding prediction of AKI post cardiac surgery [89]
Netrin Prediction of AKI post-cardiac surgery [90]
Hepcidin Correlation between lower urinary hepcidin levels and AKI post-cardiac surgery [91]
Urinary calprotectin Diff erentiation between pre-renal AKI and intrinsic AKI [10]
AKI, acute kidney injury; GFR, glomerular fi ltration rate; RRT, renal replacement therapy.
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KIM-1 and IL-18 in 249 hospitalised adult patients on the 
ﬁ rst day when AKIN criteria for AKI were met. Th ey 
found that the AUC for prediction of progression to a 
higher AKIN stage or hospital death was 0.62 using a 
clinical model including baseline glomerular ﬁ ltration 
rate (GFR), surgery, diabetes mellitus, hypertension, age 
≥65  years, body mass index, male gender and non-
Caucasian race. Th e individual addition of NGAL, KIM-1 
and IL-18 to the clinical model improved the AUC to 
0.75, 0.69 and 0.68, respectively. Nejat and colleagues [8] 
measured uNGAL, cystatin C, γ-glutamyl transpeptidase 
(γ-GT), IL-18 and KIM-1 in 529 critically ill patients at 0, 
12 and 24  hours after admission to ICU. Patients were 
stratiﬁ ed into groups having no AKI, pre-renal AKI, AKI 
with recovery within 24 to 48 hours and patients with the 
composite of AKI for >48  hours and/or treatment with 
RRT. Biomarker concentrations signiﬁ cantly and pro gress-
ively increased with duration of AKI. In patients deﬁ ned 
as having pre-renal AKI, urinary cystatin C, IL-18 and 
KIM-1 levels were signiﬁ cantly higher compared to 
patients without AKI, and signiﬁ cantly lower when com-
pared to patients with AKI for >48  hours or patients 
need ing RRT. Th ere was no signiﬁ cant diﬀ erence for 
uNGAL and γ-GT levels between patients with pre-renal 
AKI versus no AKI. Singer and colleagues [9] explored 
the use of uNGAL in diﬀ erentiating between pre-renal 
and intrinsic AKI in patients with a raised serum creati-
nine. On adjudication by two clinicians, 26% of the 
patients were labelled as unclassiﬁ able as their clinical 
and laboratory parameters did not conform to traditional 
pre-renal or AKI criteria. While the NGAL results gener-
ally tracked the patients who were classiﬁ ed as having 
pre-renal or AKI, disappointingly there was considerable 
overlap of NGAL values in the unclassiﬁ able group. 
Finally, Heller and colleagues [10] recently explored the 
role of urinary calprotectin, a mediator protein of the 
innate immune system, in diﬀ erentiating between pre-
renal AKI and intrinsic AKI. A cohort of 101 hospitalised 
patients was studied, including 34 patients with pre-renal 
AKI and 52 patients with intrinsic AKI of whom over 
40% had a urinary tract infection. Th e median urinary 
calprotectin was signiﬁ cantly higher in intrinsic AKI than 
in pre-renal AKI. Importantly, there was no signiﬁ cant 
diﬀ erence between healthy controls and patients with 
pre-renal AKI. Th e AUC for urinary calprotectin for 
predicting intrinsic AKI was 0.97.
In conclusion, given the wide variation between 
studies, no single biomarker can currently be recommen-
ded to diﬀ erentiate reliably between pre-renal AKI and 
intrinsic AKI.
‘Early’ diagnosis of acute kidney injury
Many investigations have focussed on the ability of bio-
markers to diagnose AKI before a detectable serum 
creati nine rise. Cruz and colleagues [11] measured plasma 
NGAL (pNGAL) in 301 heterogenous ICU patients and 
showed that it allowed the diagnosis of AKI up to 
48  hours prior to AKI according to the RIFLE criteria 
with an AUC of 0.78. Of note, there was also a strong 
association between pNGAL and overall disease severity 
regardless of the presence of AKI. In another study 
involving 88 patients, a single pNGAL measurement on 
admission to ICU predicted the onset of AKI 48  hours 
before AKI as per RIFLE criteria with an impressive AUC 
of 0.92 [12]; however, the study was small and patients 
with a history of CKD were excluded. In contrast, Endre 
and colleagues [13] evaluated 6 urinary biomarkers 
(NGAL, KIM-1, IL-18, alkaline phosphatase, γ-GT and 
cystatin C) prospectively in 529 patients on admission to 
ICU and found that no biomarker had an AUC above 0.7 
in the prediction of AKI, RRT or mortality. De Geus and 
colleagues [14] assessed the ability of pNGAL and 
uNGAL to predict severe AKI prospectively in a cohort 
of 632 consecutive adult critically ill patients. Samples for 
measurement of NGAL were obtained on admission and 
thereafter at 4, 8, 24, 36 and 72  hours. A total of 171 
(27%) patients developed AKI according to the RIFLE 
classiﬁ cation during the ﬁ rst week of ICU stay. Th ere was 
a signiﬁ cant association between patients’ pNGAL and 
uNGAL levels on ICU admission and the ﬁ nal RIFLE 
class. Combining both biomarkers with 13 clinical and 
laboratory parameters in a logistic regression model 
improved the prediction for RIFLE Failure. However, 
there was no validation cohort. Also, 29.8% of patients 
with sepsis had elevated uNGAL levels without AKI as 
deﬁ ned by the RIFLE criteria.
Several studies have demonstrated that measurement of 
plasma cystatin C concentrations may be a useful tool to 
diagnose AKI early but its superiority over serum 
creatinine has not been universally demonstrated. A recent 
meta-analysis by Zhang and colleagues [15] included 13 
studies and found that the AUC of plasma cystatin C to 
predict AKI was between 0.86 to 0.96 depending on the 
inclusion criteria employed. In contrast, urinary cystatin C 
levels had only moderate diagnostic value, with a pooled 
AUC of 0.64 (95% conﬁ dence interval (CI) 0.62 to 0.66). 
Th e conclusions of the meta-analysis were limited by great 
heterogeneity of pooled studies, in terms of clinical setting, 
deﬁ nition of AKI, timing of plasma/urinary cystatin C 
measurement and type of assay used. Royakkers and 
colleagues [16] measured serial plasma and urinary 
cystatin C prospect ively in 151 ICU patients and assessed 
the performance for AKI prediction on day  1 and day  2 
before the RIFLE criteria for AKI were met. On day  2, 
plasma and urinary cystatin C had an AUC for predicting 
AKI of 0.72 and 0.49, respectively. On day  1, the AUCs 
were respect ively 0.62 and 0.46. Of note, plasma cystatin C 
levels did not rise earlier than serum creatinine.
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Doi and colleagues [17] measured 5 diﬀ erent urinary 
biomarkers (L-FABP, NGAL, cystatin C, IL-18 and albu-
min) in 339 critically ill adult patients on admission to a 
medical-surgical ICU of whom 131 developed AKI as 
deﬁ ned by the RIFLE criteria. In this cohort, the best 
urinary biomarker to detect AKI was L-FABP with an 
AUC of 0.75 (95% CI 0.69 to 0.80).
Outside the ICU, the predictive potential of pNGAL for 
AKI, compared to serum creatinine, was assessed in 207 
consecutive patients presenting to the emergency depart-
ment with acute heart failure [18]. pNGAL was measured 
in a blinded fashion at presentation and serially there-
after. Sixty patients (29%) developed AKI according to 
the AKIN criteria. After control for pre-existing chronic 
cardiac or kidney disease in a multivariate regression 
analysis, serum creatinine, but not NGAL, remained an 
independent predictor of AKI (hazard ratio 1.15; 95% CI 
1.01 to 1.31; P  =  0.04). In a separate study including 
emer gency patients with suspected sepsis at risk of AKI, 
Shapiro and colleagues [19] found that a cutoﬀ  pNGAL 
value of >150 ng/ml demonstrated a sensitivity of 81% for 
predicting RIFLE Risk and 93% for prediction of RIFLE 
Injury; however, speciﬁ city was poor at 51% (95% CI 47 
to 55%).
In conclusion, the diagnostic utility of NGAL or other 
biomarkers to diagnose AKI prior to elevations in creati-
nine varies between diﬀ erent patient populations and is 
aﬀ ected by comorbidity, timing of the measurements 
and, importantly, the chosen cutoﬀ  values. Herein lies 
one of the fundamental problems besetting the evaluation 
and interpretation of any new biomarker for AKI. At 
present the best routinely applied test for renal function 
and presumed GFR is that of serum creatinine. Th is is far 
from a robust gold standard and is beset with problems 
in the acute setting and in particular in the ICU patient 
with inherent problems associated with creatine 
production rates as well as ﬂ uctuating volumes of 
distribution.
Prediction of outcome
Diﬀ erent outcomes have been evaluated in clinical studies, 
including severity and progression of AKI, need for RRT, 
ICU and hospital mortality, and progression to CKD. In a 
prospective multicenter observational cohort study of 
380 adults with conﬁ rmed AKI stage 1 as per AKIN 
criteria after cardiac surgery, Koyner and colleagues [20] 
evaluated the role of urinary IL-18, urinary albumin to 
creatinine ratio (ACR), and uNGAL and pNGAL in 
predicting risk of progression of AKI. After adjustment 
for clinical predictors, an ACR >133 mg/g at the time of 
AKI denoted 3.4-fold odds of AKI progression compared 
with an ACR <35  mg/g, and a urine IL-18 level >185 
showed a three-fold risk of progression compared with 
lower levels. uNGAL levels were not statistically 
signiﬁ  cant after adjustment of clinical variables. A 
pNGAL level >323 ng/ml performed the best, conveying 
an over seven-fold risk of AKI progression compared to 
patients with lower values.
Mortality is a common outcome in several biomarker 
studies. Bell and colleagues [21] demonstrated that 
among a mixed ICU population, plasma cystatin C levels 
on admission correlated with mortality both in ICU 
patients with or without AKI. Doi and colleagues [17] 
showed that a combination of uNGAL, urinary cystatin C 
and IL-18 predicted 14-day mortality with an impressive 
AUC of 0.93 (95% CI 0.95 to 0.94). In contrast, Nejat and 
colleagues [22] reported that plasma cystatin C levels on 
ICU admission were predictive of death within 30  days 
but the observed AUC was only 0.63 (95% CI 0.56 to 
0.72). Th us, plasma cystatin C appears to be a good bio-
marker to estimate GFR and to detect any deterioration 
earlier than serum creatinine but its ability to reliably 
predict AKI, RRT requirement or ICU/hospital death 
remains uncertain.
Recovery of renal function is another important clinical 
outcome. Th e ability of pNGAL to predict the recovery 
from AKI was demonstrated in a post hoc analysis of a 
multicenter, prospective, cohort study of 180 patients 
with community-acquired pneumonia and AKI (deﬁ ned 
as RIFLE Failure) [23]. pNGAL alone predicted failure to 
recover from AKI with an AUC of 0.74 (95% CI 0.66 to 
0.81), similar to a clinical model using age, serum creati-
nine, pneumonia severity, and non-renal organ failure 
with an AUC of 0.78. Importantly, combining the clinical 
model with pNGAL concentrations did not improve 
predictive ability.
uNGAL and pNGAL have also been studied as 
predictors of graft function after renal transplantation. 
Hollmen and colleagues [24] measured NGAL values in 
99 consecutive deceased kidney donors in the ICU (176 
recipients) and found that increased donor uNGAL level 
but not pNGAL predicted an increase in observed 
histological changes in subsequent donor kidney biop-
sies, an increase in delayed graft function beyond 14 days 
and worse 1-year graft survival. In a smaller prospective 
study, pNGAL was evaluated in a cohort of 41 deceased 
kidney donors, and in contrast to the work of Hollmen 
and colleagues, pNGAL was superior to serum creatinine 
in predicting delayed graft function [25].
Triggers for renal replacement therapy
As discussed, some AKI biomarkers have the capacity, 
either alone or integrated with traditional renal function 
tests, to predict the need for RRT in a variety of clinical 
settings [26] (Table  3). Herget-Rosenthal and colleagues 
[27] measured plasma cystatin C daily in 85 patients (44 
patients with AKI and 41 controls) in 3 German medical 
and surgical ICUs and showed that an increase by ≥50% 
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predicted the requirement of RRT with AUCs of 0.69 
(95% CI 0.51 to 0.84) when measured 2  days prior to 
developing AKI as per RIFLE criteria, 0.75 (95% CI 0.62 
to 0.85) one day prior to AKI, and 0.76 (95% CI 0.62 to 
0.89) on the day of RIFLE Risk. Of note, the precise 
indications for RRT were not provided. In contrast, 
Perianayagam and colleagues [28] measured plasma 
cystatin C levels in 200 hospitalised patients with AKI at 
the time of nephrology consultation and showed that 
cystatin C performed no better than traditional indices of 
kidney injury (blood urea nitrogen, serum creatinine and 
urine output) in predicting RRT requirement or in-
hospital death (AUC 0.65; 95% CI 0.58 to 0.73). Similarly, 
in the previously cited study by Royakkers and colleagues 
[16], plasma and urine cystatin C at the onset of AKI 
were poor predictors for the need of RRT, with AUCs of 
0.66 and 0.61, respectively. Liangos and colleagues [29] 
measured urinary KIM-1 and N-acetyl-β-D-glucosamini-
dase in 201 hospitalised patients with AKI and found that 
both biomarkers in combination with cirrhosis, sepsis, 
oliguria and mechanical ventilation yielded an AUC of 
0.78 (95% CI 0.71 to 0.84) in predicting need for RRT or 
mortality. However, one wonders whether clinical evalua-
tion alone would not predict this outcome equally well.
Although data conﬁ rm that a higher biomarker level is 
often associated with RRT, there is still insuﬃ  cient evi-
dence to conclude that biomarkers can be used routinely 
to decide when to initiate RRT. In clinical practice, the 
decision to start RRT is usually inﬂ uenced not only by 
serum creatinine but by multiple factors, including 
indivi dual physician practice, degree of azotaemia, 
acidosis and ﬂ uid overload and severity of illness of the 
patient as well as organisational or logistical factors. 
Future studies will have to explore whether speciﬁ c 
biomarkers can indeed identify AKI that is so severe that 
spontaneous recovery is unlikely to occur and RRT is 
needed, and whether they can be integrated into clinical 
RRT decision algorithms.
Applicability of new AKI biomarkers in clinical 
practice
Th e performance of diﬀ erent urinary and plasma bio-
markers for AKI has been very variable with AUCs 
quoted between 0.3 and 1.0 [30]. Studies with higher 
AUC values often included homogenous populations 
with a well-deﬁ ned single injury to the kidney, such as 
those patients receiving contrast, after cardiac surgery or 
following transplantation. In more heterogenous popu-
lations including critically ill patients in the ICU or 
emergency department where time of onset of renal 
injury is variable, the biomarkers tend to perform less 
well with lower derived AUC values.
Th e time at which biomarker levels are measured 
clearly inﬂ uences their test performance. With the rapid 
changes in pNGAL and uNGAL concentrations, the slow 
changes in serum creatinine, and the eﬀ ects of intensive 
resuscitation and ﬂ uid administration in the ﬁ rst hours 
after ICU admission, timing of NGAL measurement in 
relation to serum creatinine aﬀ ects interpretation. In 
previous studies in ICU patients, NGAL measurement 
ranged from 48  hours after the initiation of mechanical 
ventilation to within 24 hours of admission to the initial 
presentation in the ICU. In the aforementioned paper by 
De Geus and colleagues [14], 58% of all patients with AKI 
already had obvious AKI on admission to ICU. Similarly, 
Nickolas and colleagues [31] reported that a uNGAL 
level >85  μg/g creatinine was an excellent predictor of 
AKI in the emergency department setting with an AUC 
of 0.95. However, the mean serum creatinine of the entire 
AKI subgroup at presentation in the emergency depart-
ment was 495 μmol/L (standard deviation 486), indicat-
ing that severe loss of renal function had already 
occurred, and was apparent, in most patients. Ideally, test 
results generated in patients with established AKI should 
not be used for the comparison with those in a cohort at 
risk of developing AKI.
Recent studies in healthy volunteers have also empha-
sized that there may be gender-related diﬀ erences (that 
is, higher NGAL levels in women) and age-related varia-
tions in biomarker levels [32]. Th is uncertainty about the 
exact cutoﬀ  values to diﬀ erentiate normal renal function 
from AKI, coupled with poor performance in patients 
with pre-existing CKD or other comorbidities, has 
signiﬁ cantly limited the utility of AKI biomarkers [13,33]. 
In a cohort of patients following cardiopulmonary bypass 
surgery, McIlroy and colleagues [33] showed that uNGAL 
was only predictive of AKI in patients with normal renal 
function before surgery but not in patients with CKD. 
Finally, there is an ongoing debate about the interpre-
tation of urinary biomarkers and whether it is necessary 
to normalize the values to urinary creatinine [34,35].
An ideal biomarker should provide additional informa-
tion that is not surmised from clinical evaluation and 
traditional tests. Although numerous studies have con-
ﬁ rmed that various biomarkers indeed predict AKI 
earlier than serum creatinine alone, their superiority over 
clinical models is uncertain. Th e danger is that indis-
criminate use of biomarkers may distract from adequate 
clinical evaluation and result in worse patient outcomes 
as well as consuming signiﬁ cant resources. Siew and 
colleagues [36] showed that NGAL added little to clinical 
prediction in discriminating AKI in a general ICU 
population. De Geus and colleagues [5] conﬁ rmed that 
serial uNGAL results were superior to pNGAL and 
cystatin C in diﬀ erentiating between transient and 
sustained AKI on admission to ICU but adding uNGAL 
to a prediction model with clinical parameters improved 
the model only marginally. Singer and colleagues [9] 
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showed that NGAL results generally tracked the patients 
classiﬁ ed as having pre-renal or AKI but there was 
considerable overlap of NGAL values in the unclassiﬁ able 
group. Th is inability of NGAL to improve the classiﬁ -
cation of the unclassiﬁ able patients, in whom it would 
have the most value, illustrates some of the gaps in our 
current knowledge.
Finally, some studies have shown that the predictive 
property of various biomarkers improves with increased 
frequency of measurements. However, whether frequent 
measurements several times a day are practical and cost-
eﬀ ective in routine clinical practice has not been 
evaluated.
Traditional markers of renal function
Current tools to diagnose AKI and to distinguish intrinsic 
AKI from pre-renal AKI include blood urea nitrogen, 
urine output and urine chemistry and microscopy.
Urea
Urea is formed by the hepatic metabolism of amino acids 
and excreted primarily by glomerular ﬁ ltration. Serum 
concentrations may vary as a result of changes in urea 
production (that is, in the context of a gastrointestinal 
bleed) and tubular urea reabsorption during hypo volae-
mic states without changes in GFR. Th is makes urea an 
unreliable marker of renal function.
Fractional excretion of sodium
Fractional excretion of sodium (FeNa) was one of the ﬁ rst 
urine chemistries applied to diﬀ erentiating pre-renal AKI 
from acute tubular necrosis (ATN). It is based on the 
premise that intact tubules reabsorb sodium in the pre-
renal setting whereas injured tubules in the context of 
ATN do not. In one of the earlier studies from 1976, 
Espinel [37] showed in 17 highly selected patients with 
oliguric AKI that FeNa was <1% in pre-renal AKI and 
>3% in ATN. Subsequently, numerous authors described 
various forms of ATN with FeNa <1% and prerenal AKI 
with FeNa >1%. One of the major reasons for reduced 
FeNa utility relates to the fact that various acute diseases 
disturb the typical tubular response and make FeNa 
poorly reﬂ ective of the actual cause of AKI during acute 
illness [38]
Urine microscopy
Small studies have shown the utility of urine microscopy 
in diﬀ erentiating pre-renal AKI from ATN. Th e back-
ground is that an ischemic or nephrotoxic insult to the 
tubules results in apoptosis or necrosis of renal tubular 
epithelial cells, which are shed into the tubular lumen 
and excreted free or as casts. In contrast, in pre-renal 
AKI, urine microscopy typically shows a bland sediment 
or hyaline casts. However, pre-renal AKI and ATN are a 
spectrum and may sometimes coexist. Marcussen and 
colleagues [39] performed urine microscopy in 51 
patients with hospital-acquired AKI who had pre-renal 
AKI, ‘non-ATN’ AKI, or ATN. Th ey found that the 
number of urinary cells and granular casts correlated 
with the rise in serum creatinine (that is, worsening AKI). 
In addition, patients who needed RRT had more casts 
than patients who did not require RRT. In 2008, Chawla 
and colleagues [40] demonstrated that an ‘AKI cast 
scoring index’ based on tubular and granular casts was 
useful in predicting severity and non-recovery from AKI. 
In 2010, Perazella and colleagues [41] used urine micros-
copy and a modiﬁ ed urine sediment score to evaluate the 
outcome of AKI in 197 patients with pre-renal AKI or 
ATN. Th e urine sediment score was predictive of 
progres sive AKI, need for RRT and death.
Th us, urine microscopy appears to have utility not only 
in diﬀ erentiating AKI but also in predicting severity of 
AKI and outcome. Although it is inexpensive and readily 
available, it requires training and experience and is time 
consuming. Th e ﬁ rst study to compare traditional urinary 
biomarkers (including urine microscopy) with novel 
biomarkers was performed by Bagshaw and colleagues 
[42] in 83 septic and non-septic ICU patients with AKI. 
In a prospective, two-centre cohort study, they examined 
the utility of a urine microscopy score, urine chemistry 
and pNGAL/uNGAL in predicting worsening renal 
function, need for RRT, and death. Th e urine microscopy 
score was higher in septic patients with AKI, correlated 
with uNGAL (r = 0.41; P = 0.012), predicted worsening 
AKI and was associated with greater likelihood of RRT or 
death. Urine chemistry (urine sodium, FeNa) was not 
associated with the clinical outcomes. Th e authors con-
clu ded septic AKI was associated with greater urine 
microscopy evidence of kidney injury compared with 
non-septic AKI, that a higher urine microscopy score 
correlated with higher uNGAL and that urine microscopy 
and uNGAL were complementary in predicting worsen-
ing AKI in ICU patients.
In conclusion, on the basis of the current information, 
it appears that urine microscopy and new urine bio-
markers may be used together to inform on early AKI, 
diﬀ erentiate pre-renal AKI from ATN, and predict 
progres sive AKI, need for RRT and death. In contrast, 
urine chemistry may provide some insight into diﬀ eren-
tial diagnosis when used in select patients but has little 
role in most hospitalized patients with AKI.
Urine output
Multiple mechanisms can potentially cause a low urine 
output in the acutely injured kidney. Proponents argue 
that urine output is a valuable renal biomarker which 
often portends renal dysfunction in critical care patients 
before changes in serum creatinine [43,44]. In contrast, 
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critics point out that urine output is aﬀ ected by volume 
status, intrinsic levels of antidiuretic hormone, presence 
of obstruction, and use of diuretics, and that urine 
volumes can only be accurately assessed in patients with 
a urinary catheter.
Macedo and colleagues [45] performed  hour-to-hour 
urine collections in a cohort of 317 critically ill surgical 
patients who did not have AKI, pre-existing CKD stage 5, 
a functioning renal transplant, liver cirrhosis or severe 
anaemia. Daily and cumulative ﬂ uid balance were 
collected between ICU admission and discharge, and 
admission serum creatinine was considered the reference 
value. Detailed ﬂ uid and diuretic administration were not 
recorded. Th e authors showed that signiﬁ cant renal injury 
was likely when patients showed persistent, consis tent 
oliguria for 6 hours or more. Th ey also showed an earlier 
detection of AKI by oliguria rather than serum creatinine. 
Although urine output is a criterion in both the RIFLE and 
AKIN classiﬁ cation, the data are far from robust, and 
despite the fact that oliguria is often a portend of a renal 
insult, we do not fully appreciate the signiﬁ cance nor the 
mechanisms involved in the critically ill [46].
Unanswered questions
Th e new biomarkers of AKI have enhanced our under-
standing of some of the biological and biochemical 
processes during AKI; however, to date their clinical 
utility remains unclear. It is not known whether any of 
the new biomarkers add anything beyond clinical evalu-
ation and traditional renal function tests and whether 
they can guide clinical management and ultimately alter 
the outcome of patients with AKI. Th ere is also concern 
that a single biomarker may not be able to fulﬁ l all criteria 
as outlined in Table  1, and that it is more realistic to 
search for a panel of diﬀ erent biomarkers that, in combi-
nation, may provide the necessary data to manage 
patients with AKI.
Critics have also pointed out that the beneﬁ t of early 
diagnosis of AKI is questionable given the fact that there 
is no speciﬁ c cure for AKI yet. Th at is true, but this also 
reﬂ ects the fact that AKI is not one disease and, as such, a 
speciﬁ c cure is unlikely. A case could be made that early 
diagnosis of AKI may avoid further harm, that is, 
avoiding nephrotoxic drug administration or premature 
discharge from the emergency department or ICU.
Some studies have demonstrated that biomarkers may 
be elevated without overt changes in serum creatinine. In 
a pooled analysis of aggregate data from 10 studies 
including 2,322 patients, 19.2% of patients had raised 
NGAL levels without relevant changes in serum 
creatinine [47]. Mortality, length of stay in ICU and need 
for RRT were signiﬁ cantly higher in this cohort compared 
to patients without NGAL and creatinine rises. Whether 
NGAL in these circumstances is an indicator of 
sub clinical renal injury (as suggested by the authors) or 
simply a marker of severity of illness remains unclear.
Despite numerous unanswered questions and un cer-
tain ties, the discovery of new biomarkers for AKI has 
opened the doors to a better understanding of the 
processes involved in AKI. More studies are necessary to 
improve our interpretation of biomarker values. Previous 
studies have concentrated on comparing the results with 
changes in serum creatinine, and the performance of 
biomarkers, including the AUC, was judged by the level 
of agreement. Given the well known pitfalls of serum 
creatinine, however, it is possible that this approach is 
ﬂ awed and may account for some of the inconsistent and 
contradictory ﬁ ndings in the literature. Ultimately, 
clinical usefulness of a set of markers will be determined 
not only by accuracy and reliability in prediction but also 
by whether that information alters therapy and whether 
this translates into an improvement in clinical outcomes.
Th e main potential for new biomarkers are: to identify 
the pathogenetic/pathophysiological pathways involved 
in the development of AKI; to function both as screening 
and monitoring tools for future intervention trials; and to 
potentially measure renal cellular injury in drug 
development projects.
It is likely that the biomarker proﬁ le of AKI post-
cardiac surgery is diﬀ erent from that of septic AKI or 
toxin-induced AKI. Patterns of AKI biomarkers may have 
the potential to discriminate between the various mecha-
nisms and anatomical sites of diﬀ erent types of acute 
renal injury. In addition, clinicians are interested in 
knowing whether new biomarkers can be utilised to 
change management and outcome of AKI. Two potential 
study designs with incorporation of biomarkers have 
already been proposed [48]. In the ﬁ rst design, patients 
are randomly assigned to have the marker measured, and 
those with an increase are treated. In the second design, 
all patients have the marker measured and those with 
increased levels are randomly assigned to treatment or 
not. One such trial was performed by Endre and 
colleagues [49], who investigated in a double-blind 
placebo-controlled study whether early treatment with 
high dose erythropoietin could prevent the development 
of clinically diagnosed AKI in ICU patients. Th e decision 
to randomly assign patients was based solely on a three-
fold rise in urinary γ-GT and alkaline phosphatase but 
not on any other traditional factors. Although the study 
was negative and erythropoietin was not successful in 
preventing AKI, RRT or death, it serves as an example of 
how to conduct future clinical trials. In addition, bio-
markers may be used as surrogate markers for response 
to treatment or markers of recovery from AKI, including 
the timing of discontinuing RRT.
Finally, early markers of nephrotoxicity have the 
potential to facilitate the development of safer new drugs 
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[50]. Th ey may indicate renal injury earlier than conven-
tional methods, plus reduce the need for more invasive 
investigations, including renal biopsies. Following studies 
involving international centres and major pharmaceutical 
companies, the US Food and Drug Administration (FDA) 
and the European Medicines Agency (EMEA) have 
accepted multiple rodent urinary and plasma biomarkers 
as surrogates for renal histology for preliminary evalua-
tion and monitoring of nephrotoxicity in drug develop-
ment and monitoring during post-marketing surveillance 
[51].
In conclusion, the recognition that relatively trivial 
rises in creatinine may herald potentially disastrous 
sequelae for patients has led to an increased awareness of 
potential AKI. Hopefully, the advent of new biomarker(s) 
will lead to adoption of diﬀ erent methods of deﬁ ning the 
kidney at risk rather than relying simply on creatinine. In 
clinical practice we already employ excellent biomarkers, 
such as highly sensitive troponin I, which has recently 
been shown to have an AUC of 0.96 for diagnosing acute 
myocardial infarction [52]. Although now fully estab-
lished in clinical practice, it is important to acknowledge 
that it took years for measurement of troponin to become 
a routine clinical investigation in patients with cardiac 
chest pain. To date, none of the new AKI biomarkers 
have undergone a similar rigorous assessment but the 
current progress will hopefully lead to success and ulti-
mately to improvement in patient outcomes.
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